Jun Yan

Prof. Dr. Jun Yan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
Liusheng WuLiusheng Wu
Liusheng Wu
XLXiaoqiang Li
Xiaoqiang Li
XQXinye Qian
Xinye Qian
SWShuang Wang
Shuang Wang
JLJixian Liu
Jixian Liu
JYJun Yan
Jun Yan
In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great research interest. mRNA vaccines are a potential choice for tumor immunotherapy, due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery carrier, and their structural stability and biocompatibility make them an effective means for delivering mRNA to specific targets. This study summarizes the research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity, and targeting is discussed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy, as well as to provide more effective treatment plans for patients.

29 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Liusheng WuLiusheng Wu
Liusheng Wu
QLQi Liu
Qi Liu
XRXin Ruan
Xin Ruan
XLXinyu Luan
Xinyu Luan
YZYanfeng Zhong Yanfeng Zhong
Yanfeng Zhong Yanfeng Zhong
XLXiaoqiang Li
Xiaoqiang Li
Objective: The RNA-binding protein RBM10 can regulate apoptosis during the proliferation and migration of pancreatic cancer, endometrial cancer, and osteosarcoma cells; however, the molecular mechanism underlying lung adenocarcinoma is rarely reported. Recent studies have detected multiple truncated and missense mutations in RBM10 in lung adenocarcinoma, but the role of RBM10 in lung adenocarcinoma is unclear. This study mainly explored the immune regulation mechanism of RBM10 in the development of lung adenocarcinoma and its influence on sensitivity to targeted therapy drugs. Methods: The transcriptome data of CGAP were used to analyze the RNA-seq data of lung adenocarcinoma patients from different subgroups by using the CIBERSORT algorithm to infer the relative proportion of various immune infiltrating cells, and Spearman correlation analysis was performed to determine the gene expression and immune cell content. In addition, this study utilized drug trial data from the GDSC database. The IC50 estimates for each specific targeted therapy were obtained by using a regression method, and the regression and prediction accuracy were tested via ten cross-validations with the GDSC training set. An immunohistochemical test was performed on the samples of 20 patients with lung adenocarcinoma in the subcomponent analysis of immune cells, and the protein expression of RBM10 in lung adenocarcinoma tissues was verified by cellular immunofluorescence assays. Nucleic acids were extracted at low temperatures, and qRT-PCR was used to verify the expression levels of the mRNA of RBM10 in lung adenocarcinoma tissues and normal tissues (p < 0.05). Results: After screening and inclusion using a machine language, the results showed that RBM10 was significantly highly expressed in the lung adenocarcinoma tissues. The related signaling pathways were mainly concentrated in ncRNA processing, rRNA metabolic processes, ribosome biogenesis, and the regulation of translation. The qRT-PCR for 20 lung adenocarcinoma tissues showed that the expression of RBM10 in these tissues was significantly different from that in normal tissues (p = 0.0255). Immunohistochemistry analysis and cell immunofluorescence staining also confirmed that RBM10 was involved in the immune regulation of lung adenocarcinoma tissues, and the number of immune cell aggregations was significantly higher than that of the control group. RBM10 regulates B cell memory-CIBERSORT (p = 0.042) and B cell memory-CIBERSOTRT-abs (p = 0.027), cancer-associated fibroblast-EPIC (p = 0.001), cancer-associated fibroblast- MCPCounter (p = 0.0037), etc. The risk score was significantly associated with the sensitivity of patients to lapatinib (p = 0.049), nilotinib (p = 0.015), pazopanib (p = 0.001), and sorafenib (p = 0.048). Conclusions: RBM10 can inhibit the proliferation and invasion of lung adenocarcinoma cells through negative regulation and promote the apoptosis of lung adenocarcinoma cells through immunomodulatory mechanisms. The expression level of RBM10 affects the efficacy of targeted drug therapy and the survival prognosis of lung adenocarcinoma patients, which has a certain guiding significance for the clinical treatment of these patients.

10 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Liusheng WuLiusheng Wu
Liusheng Wu
YZYanfeng Zhong Yanfeng Zhong
Yanfeng Zhong Yanfeng Zhong
DWDingwang Wu
Dingwang Wu
PXPengcheng Xu
Pengcheng Xu
XRXin Ruan
Xin Ruan
XLXiaoqiang Li
Xiaoqiang Li
[Objective] Using multi-omics research methods to explore cytolytic activity-related genes through the immunoregulatory factors HAVCR2 (TIM3) affecting the survival and prognosis of lung adenocarcinoma. [Methods] We combined Cox single factor regression and lasso regression feature selection algorithm to screen out the key genes of cytolytic activity in lung adenocarcinoma, and applied multi-omics research to explore the clinical predictive value of the model, including onset risk, independent prognosis, clinical relevance, signal transduction pathways, drug sensitivity, and the correlation of immune regulatory factors, etc. TCGA data are used as the experimental group, and GEO data is used as the external data control group to verify the stability of the model. The survival curve was generated by the Kaplan–Meier method and compared by log-rank, and the Cox proportional hazard model was used for multivariate analysis. In this study, 10 fresh tissue samples of lung adenocarcinoma were collected for cellular immunohistochemical experiments to analyze the expression of immunoregulatory factors in cancer tissues, and the key immunoregulatory factors were verified and screened out. [Results] A total of 450 genes related to cytolytic activity were differentially expressed, of which 273 genes were up-regulated and 177 genes were down-regulated. A total of 91 key genes related to cytolytic activity related to the prognosis of lung adenocarcinoma were screened through Cox single factor regression. The ROC curve results showed that the AUC values of 1, 3, and 5 years in the training set and test set were all greater than 0.7, indicating that the model has a valid verification. The level of risk score is significantly related to the sensitivity of patients to AKT inhibitor VIII, Lenalidomide, and Tipifarnib. In addition, our study also found that receptor and MHC genes related to immunomodulatory, and chemokines, including HAVCR2, are more highly expressed in the low-risk group. [Conclusions] HAVCR2 (TIM3) immunoregulatory factors affect the expression of key genes that affect cytolytic activity in lung adenocarcinoma cells, and to some extent indirectly affect the survival and prognosis of patients with lung adenocarcinoma.

3 January 2024 in International Journal of Bioprinting
Verified
Journal Article
Open access
PDF file
Liusheng WuLiusheng Wu
Liusheng Wu
HLHuansong Li
Huansong Li
YLYangsui Liu
Yangsui Liu
ZFZhengyang Fan
Zhengyang Fan
JXJingyi Xu
Jingyi Xu
JYJun Yan
Jun Yan
With the rapid development of three-dimensional (3D) bioprinting technology, the research revolving around in vitro functional pancreas and tumor models has become the focus of attention in the field of life sciences. This review aims to summarize and deeply discuss the research progress and prospects of 3D-bioprinted functional pancreas and in vitro tumor models. The efforts in improving 3D printing technology to increase its accuracy and reliability in the biomedical applications have been ramped up over the past few years. Researchers are now able to create highly complex 3D structures through precise layering of biological materials at the micron scale. For instance, a functional pancreas can be printed in vitro by combining cells, biomaterials, and growth factors. The introduction of new technologies allows researchers to more accurately simulate the growth and spread of tumors, providing a more realistic platform for cancer treatment research. This not only helps accelerate the process of drug screening, but also lays the foundation for personalized medicine. As multiple disciplines, such as materials science, cell biology, and engineering, continue to converge with 3D bioprinting, emergence of more innovative applications is anticipated. However, despite significant progress, many technical and ethical challenges still need to be overcome before practical clinical applications can be implemented. In summary, the application of bioprinting technology is of great significance to the study of functional pancreas and in vitro tumor models, which could lead to new breakthroughs in the development of clinical treatment and personalized medicine.

28 March 2024 in Heliyon
Verified
Journal Article
Open access
Liusheng WuLiusheng Wu
Liusheng Wu
XCXiaofan Chen
Xiaofan Chen
QZQi Zeng
Qi Zeng
ZLZelin Lai
Zelin Lai
ZFZhengyang Fan
Zhengyang Fan
JYJun Yan
Jun Yan
Differentially expressed genes (DEGs) in lung adenocarcinoma (LUAD) tumor stem cells were screened, and the biological characteristics of NR5A2 gene were investigated. The expression and prognosis of NR5A2 in human LUAD were predicted and analyzed through bioinformatics analysis from a human cancer database. Gene expression and clinical data of LUAD tumor and normal lung tissues were obtained from The Cancer Genome Atlas (TCGA) database, and DEGs associated with lung cancer tumor stem cells (CSCs) were screened. Univariate and multivariate Cox regression models were used to screen and establish prognostic risk prediction models. The immune function of the patients was scored according to the model, and the relative immune functions of the high- and low-risk groups were compared to determine the difference in survival prognosis between the two groups. In addition, we calculated the index of stemness based on the transcriptome of the samples using one-class linear regression (OCLR). Bioinformatics analysis of a clinical cancer database showed that NR5A2 was significantly decreased in human LUAD tissues than in normal lung tissues, and the decrease in NR5A2 gene expression shortened the overall survival and progression-free survival of patients with LUAD. The NR5A2 gene may regulate LUAD tumor stem cells through selective splicing mutations, thereby affecting the survival and prognosis of patients with lung cancer, and the NR5A2 gene may regulate CSCs through single nucleotide polymorphism.

26 June 2024 in Exploration
Verified
Journal Article
Open access
XBXue Bai
Xue Bai
JKJun Kang
Jun Kang
SWSilong Wei
Silong Wei
YWYun Wang
Yun Wang
YLYangsui Liu
Yangsui Liu
JCJin Chang
Jin Chang
Sonodynamic therapy offers a non‐invasive approach to induce the death of tumor cells. By harnessing ultrasound waves in tandem with sonosensitizers, this method produces reactive oxygen species (ROS) that inflict oxidative damage upon tumor cells, subsequently causing their demise. Ferroptosis is a regulatory form of cell death that differs from other forms, characterized by iron accumulation, ROS accumulation, and lipid peroxidation. In the presented research, a nanoparticle formulation, parthenolide/ICG‐CaCO3@lipid (PTL/ICG‐CaCO3@Lip), has been engineered to amplify ferroptosis in tumor cells, positioning it as a potent agent for sonodynamic cancer immunotherapy. This nanoparticle significantly augments ROS levels within tumor cells, inducing oxidative stress that leads to cell death. The therapeutic potential of PTL/ICG‐CaCO3@Lip, both in vivo and in vitro, has been convincingly demonstrated. Furthermore, RNA‐seq analysis insights revealed that PTL/ICG‐CaCO3@Lip facilitates tumor cell ferroptosis by regulating P53 to downregulate SLC7A11 protein expression, thereby inhibiting the glutamate‐cystine antiporter system Xc− and stimulating ACSL4/LPCAT3 pathways. This pioneering work uncovers an innovative strategy for combatting tumors, leveraging enhanced oxidative stress to promote cell ferroptosis, and paves the way for groundbreaking cancer immunotherapeutic interventions.